Subtype
Lip and Oral Cavity Carcinoma
CI-CAN-00003027Explore in graph →
96 active trials2 evidence items
- NCIt
- C9315
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003027Explore in graph →
Clinical trials
320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (40)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06031337 | Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study | completed | — | 46 | Fayoum UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06609070 | CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC | not yet recruiting | N/A | 30 | Guangzhou University of Traditional Chinese MedicineOTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT03028766 | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer(WISTERIA) | completed | Phase 1 | 9 | University of BirminghamOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599801 | Clinical Outcomes of Thoracodorsal Artery Flap in Oral and Maxillofacial Reconstruction | not yet recruiting | — | 217 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT06425146 | Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO)(TACO) | unknown | N/A | 30 | Centre Leon BerardOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05719779 | Tolerance and Benefits of Mandibular Advanced Device for Snoring and Sleep Apnea in Oropharyngeal Cancer.(Ronco-Onco) | unknown | N/A | 35 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT01847326 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | completed | Phase 1 | 48 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06438939 | NBI for Early Diagnosis of OPMD/OSCC(NBI_Oral) | not yet recruiting | N/A | 480 | Cardarelli HospitalOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05798793 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma(NEOPCOSCC) | recruiting | Phase 3 | 309 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05098119 | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT03650699 | Biofeedback Rehabilitation to Improve Speaking and Eating in Public(Biofeedback) | completed | N/A | 34 | University Health Network, TorontoOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity(INSPIRE) | completed | Phase 2 | 105 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 4 | Jan 30, 2024 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | recruiting | Phase 2 | 46 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05455632 | Postoperative Radiotherapy for Oral Squamous Cell Carcinoma After Neoadjuvant Therapy and Surgery | completed | — | 192 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04277858 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.(NECTORS) | unknown | Phase 2 | 60 | Nader SadeghiOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT01914900 | Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | completed | Phase 2 | 14 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT05708209 | The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124 | completed | — | 40 | Fayoum UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06016400 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | unknown | Phase 2 / Phase 3 | 412 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05610293 | T1 Squamous Cell Carcinomas of the Lip | unknown | — | 300 | Maastricht University Medical CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05992610 | Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy(iCHRTL) | unknown | N/A | 40 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05902455 | Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis | unknown | — | 40 | Tampere University HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03575598 | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study(SNOW) | completed | Early Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05862168 | Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial | recruiting | Phase 2 | 30 | Weijia Fang, MDOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05927220 | WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA | unknown | — | 81 | Armed Forces Institute of Pathology RawalpindiOTHER_GOV | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05904327 | Circulating Biomarkers in Oropharyngeal Cancers(CIRCOS) | active not recruiting | — | 130 | Region Örebro CountyOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05876247 | Articulatory Adaptation Following Oral Cancer Treatment(SPOKE) | unknown | — | 50 | University Medical Center GroningenOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05872880 | TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. | recruiting | — | 124 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05843032 | 3D Ultrasound, Specimen Examination by Surgeon, and MRI in Surgical Margin Assessment | unknown | N/A | 27 | Rigshospitalet, DenmarkOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05698667 | Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer | completed | N/A | 26 | Rigshospitalet, DenmarkOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05821179 | Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma | completed | — | 36 | Fayoum UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05806073 | Elective vs Therapeutic Neck Dissection in Treatment of Patients With Clinical T1/2N1M0 Oral Squamous Cell Carcinoma | not yet recruiting | N/A | 188 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05803915 | Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | unknown | Phase 2 | 57 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04413214 | Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial | completed | Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04614896 | Use of Ultrasound for Measuring Size of Oral Tongue Cancers | completed | N/A | 30 | Rigshospitalet, DenmarkOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | terminated | Early Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05766150 | Oral Microbioma and Oral Malignant Disease | unknown | — | 300 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05578170 | Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma(PROBES) | unknown | — | 47 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2024source: clinicaltrials